Akki - the "primary endpoint" is pretty important don't you...

Akki - the "primary endpoint" is pretty important don't you think?

Most of Sarepta's drugs have been passed on surrogate end points. There is still a massive question regards to their efficacy.

The FDA have defo set a precedent with their lenient assessment of Sarepta's efficacy results.

It does show how strong the parent lobby groups are - another reason why we need US based staff to be in the "inner circle", and I don't mean a US director. Perhaps Anthony needs to start working out of the US?

The monkey tox study is key - that will open up the door for serious dialogue with partners now the 9-month tox study is validated.

If we can get a number north of 30 enrollments at the half year report - the market will respond well imo.

.